Scalable expansion of iPSC and their derivatives across multiple lineages.

Autor: Kwok CK; Cell Therapy R&D, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark., Sébastien I; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Hariharan K; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Meiser I; Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany., Wihan J; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Altmaier S; Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany., Karnatz I; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Bauer D; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Fischer B; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Feile A; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany., Cabrera-Socorro A; Neuroscience Therapeutic Area, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium., Rasmussen M; Bioneer A/S, Kogle Allé 2, 2970 Hørsholm, Denmark., Holst B; Bioneer A/S, Kogle Allé 2, 2970 Hørsholm, Denmark., Neubauer JC; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany; Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany., Clausen C; Bioneer A/S, Kogle Allé 2, 2970 Hørsholm, Denmark., Verfaillie C; Department of Development and Regeneration, Stem Cell Institute, UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium., Ebneth A; Neuroscience Therapeutic Area, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium., Hansson M; Cell Therapy R&D, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark., Steeg R; Fraunhofer UK Research Ltd, Technology and Innovation Centre, 99 George Street, G1 1RD Glasgow, United Kingdom., Zimmermann H; Fraunhofer Project Center for Stem Cell Process Engineering, Fraunhofer Institute for Biomedical Engineering IBMT, Neunerplatz 2, 97082 Würzburg, Germany; Fraunhofer Institute for Biomedical Engineering IBMT, Joseph-von-Fraunhofer-Weg 1, 66820 Sulzbach, Germany; Department of Molecular and Cellular Biotechnology, Saarland University, 66123 Saarbrücken, Germany; Facultad de Ciencias del Mar, Universidad Católica del Norte, Coquimbo, Chile. Electronic address: heiko.zimmermann@ibmt.fraunhofer.de.
Jazyk: angličtina
Zdroj: Reproductive toxicology (Elmsford, N.Y.) [Reprod Toxicol] 2022 Sep; Vol. 112, pp. 23-35. Date of Electronic Publication: 2022 May 17.
DOI: 10.1016/j.reprotox.2022.05.007
Abstrakt: Induced pluripotent stem cell (iPSC) technology enabled the production of pluripotent stem cell lines from somatic cells from a range of known genetic backgrounds. Their ability to differentiate and generate a wide variety of cell types has resulted in their use for various biomedical applications, including toxicity testing. Many of these iPSC lines are now registered in databases and stored in biobanks such as the European Bank for induced pluripotent Stem Cells (EBiSC), which can streamline the quality control and distribution of these individual lines. To generate the quantities of cells for banking and applications like high-throughput toxicity screening, scalable and robust methods need to be developed to enable the large-scale production of iPSCs. 3D suspension culture platforms are increasingly being used by stem cell researchers, owing to a higher cell output in a smaller footprint, as well as simpler scaling by increasing culture volume. Here we describe our strategies for successful scalable production of iPSCs using a benchtop bioreactor and incubator for 3D suspension cultures, while maintaining quality attributes expected of high-quality iPSC lines. Additionally, to meet the increasing demand for "ready-to-use" cell types, we report recent work to establish robust, scalable differentiation protocols to cardiac, neural, and hepatic fate to enable EBiSC to increase available research tools.
(Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: